Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.200
+0.005 (2.62%)
At close: Apr 28, 2026
Northwest Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1.38 | 1.38 | 1.93 | 1.68 | 1.01 | Upgrade
|
| Revenue Growth (YoY) | -0.29% | -28.47% | 14.79% | 67.46% | -22.15% | Upgrade
|
| Cost of Revenue | 28.79 | 34.89 | 27.73 | 35.51 | 20.31 | Upgrade
|
| Gross Profit | -27.41 | -33.51 | -25.8 | -33.83 | -19.3 | Upgrade
|
| Selling, General & Admin | 32.51 | 33 | 29.71 | 33.35 | 33.4 | Upgrade
|
| Operating Expenses | 32.51 | 33 | 29.71 | 33.35 | 33.4 | Upgrade
|
| Operating Income | -59.91 | -66.51 | -55.51 | -67.18 | -52.7 | Upgrade
|
| Interest Expense | -8.7 | -7.77 | -5.24 | -6.07 | -5.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.92 | -1.55 | 2.01 | -3.3 | -1.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.57 | -0.44 | 3.57 | -25.79 | 238.7 | Upgrade
|
| EBT Excluding Unusual Items | -64.26 | -76.27 | -55.18 | -102.34 | 179.29 | Upgrade
|
| Other Unusual Items | 3.56 | -7.51 | -7.42 | -2.69 | -0.17 | Upgrade
|
| Pretax Income | -60.7 | -83.78 | -62.6 | -105.03 | 179.13 | Upgrade
|
| Income Tax Expense | -0.54 | - | - | - | - | Upgrade
|
| Net Income | -60.16 | -83.78 | -62.6 | -105.03 | 179.13 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1.32 | 1.41 | 1.77 | - | - | Upgrade
|
| Net Income to Common | -61.48 | -85.19 | -64.37 | -105.03 | 179.13 | Upgrade
|
| Shares Outstanding (Basic) | 1,457 | 1,242 | 1,119 | 1,016 | 874 | Upgrade
|
| Shares Outstanding (Diluted) | 1,457 | 1,242 | 1,119 | 1,016 | 1,008 | Upgrade
|
| Shares Change (YoY) | 17.26% | 10.99% | 10.17% | 0.79% | 38.99% | Upgrade
|
| EPS (Basic) | -0.04 | -0.07 | -0.06 | -0.10 | 0.21 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.07 | -0.06 | -0.10 | -0.06 | Upgrade
|
| Free Cash Flow | -46.27 | -58.03 | -57.07 | -55.68 | -44.31 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.05 | -0.06 | -0.04 | Upgrade
|
| Operating Margin | -4347.90% | -4812.45% | -2873.09% | -3991.74% | -5243.98% | Upgrade
|
| Profit Margin | -4461.32% | -6164.40% | -3331.94% | -6240.76% | 17823.48% | Upgrade
|
| Free Cash Flow Margin | -3357.55% | -4199.06% | -2954.14% | -3308.20% | -4409.35% | Upgrade
|
| EBITDA | -57.85 | -64.76 | -53.98 | -65.93 | -52.38 | Upgrade
|
| D&A For EBITDA | 2.06 | 1.74 | 1.53 | 1.25 | 0.32 | Upgrade
|
| EBIT | -59.91 | -66.51 | -55.51 | -67.18 | -52.7 | Upgrade
|
| Revenue as Reported | 1.38 | 1.38 | 1.93 | 1.68 | 1.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.